X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
FRESENIUS KABI ONCOLOGY LTD. Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

FRESENIUS KABI ONCOLOGY LTD.  (DBPH)


Here is the latest financial fact sheet of Fresenius Kabi Onco.. For more details, see the Fresenius Kabi Onco. quarterly results and Fresenius Kabi Onco. share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
fresenius kabi onco. - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 132.5       No. of shares m 158.23
    Mkt Cap Rs m 20,958       % ch % 0.3
    Vol '000 91.5       % ch week % 0.4
    P/E X 22.1       % ch 1-mth % 1.9
    P/CF X 19.7       % ch 12-mth % 20.1
    EPS (TTM) Rs 6.0       52 week H/L Rs 161.4/93.1
(As on Jan 2, 2014 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-09
*
12
Mar-10
*
12
Mar-11
12
Mar-12
12
Mar-13
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs81163194165176 
Low Rs2935828279 
Sales per share (Unadj.) Rs19.730.226.133.337.7 
Earnings per share (Unadj.) Rs-9.2-2.13.13.25.1 
Diluted earnings per shareRs-9.2-2.13.13.25.1 
Cash flow per share (Unadj.) Rs-7.4-0.14.24.76.7 
Dividends per share (Unadj.) Rs00000 
Adj. dividends per shareRs0.000.000.000.000.00 
Dividend yield (eoy) %00000 
Book value per share (Unadj.) Rs17.815.734.237.542.5 
Adj. book value per shareRs17.815.734.237.542.5 
Shares outstanding (eoy) m158.23158.23158.23158.23158.23 
Bonus/Rights/Conversions  PI---- 
Price / Sales ratio x2.83.35.33.73.4 
Avg P/E ratio x-6.0-47.044.338.425.0 
P/CF ratio (eoy) x-7.4-1,103.233.026.118.9 
Price / Book Value ratio x3.16.34.03.33.0 
Dividend payout %00000 
Avg Mkt Cap Rs m8,70315,66521,83619,54120,135 
No. of employees `0000.80.91.11.11.2 
Total wages/salary Rs m1,008695561610703 
Avg. sales/employee Rs Th3,789.65,088.43,649.64,784.55,176.2 
Avg. wages/employee Rs Th1,222.9738.9496.1553.9610.4 
Avg. net profit/employee Rs Th-1,772.0-354.9435.4462.7699.6 
  INCOME DATA
Net Sales Rs m3,1234,7834,1285,2685,963 
Other income Rs m223140592918 
Total revenues Rs m3,3464,9234,1875,2975,981 
Gross profit Rs m-1,2342277376591,430 
Depreciation Rs m282319169240258 
Interest Rs m291322-47177-26 
Profit before tax Rs m-1,585-2756732721,216 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m153027445-68 
Tax Rs m2859208208342 
Profit after tax Rs m-1,460-334492509806 
Gross profit margin %-39.54.717.812.524.0 
Effective tax rate %-1.8-21.430.876.328.1 
Net profit margin %-46.8-7.011.99.713.5 
  BALANCE SHEET DATA
Current assets Rs m3,5635,4205,4524,6795,102 
Current liabilities Rs m3,5444,5963,8382,0902,385 
Net working cap to sales %0.617.239.149.245.6 
Current ratio x1.01.21.42.22.1 
Inventory Days Days166187183129150 
Debtors Days Days11798156140113 
Net fixed assets Rs m4,8975,2803,5394,4535,148 
Share capital Rs m158158158158158 
"Free" reserves Rs m2,6422,3092,4695,7506,556 
Net worth Rs m2,8112,4825,4135,9266,732 
Long term debt Rs m2,0163,602952952952 
Total assets Rs m8,53710,78410,5929,21310,388 
Interest coverage x-4.40.1-13.42.5-45.8 
Debt to equity ratio x0.71.50.20.20.1 
Sales to assets ratio x0.40.40.40.60.6 
Return on assets %-13.7-0.14.27.47.5 
Return on equity %-51.9-13.49.18.612.0 
Return on capital %-23.60.810.313.014.6 
Exports to sales %59.174.280.877.274.5 
Imports to sales %16.315.819.318.724.8 
Exports (fob) Rs m1,8463,5513,3354,0694,441 
Imports (cif) Rs m5087547969861,477 
Fx inflow Rs m1,9573,6103,3614,0725,298 
Fx outflow Rs m9089559911,2501,772 
Net fx Rs m1,0492,6542,3702,8223,525 
  CASH FLOW
From Operations Rs m -1,867 -724 500 1,743 1,274 
From Investments Rs m 535 -661 -1,157 168 -1,204 
From Financial Activity Rs m 1,409 1,504 492 -1,965 -196 
Net Cashflow Rs m 77 120 -165 -54 -126 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for fresenius kabi oncology ltd.

 Share Holding
Indian Promoters : 0.0%
Foreign collaborators : 81.0%
Indian inst/Mut Fund : 0.3%
FIIs : 9.6%
ADR/GDR : 0.0%
Free float : 9.1%
Shareholders : 42,599
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: B-310, Som Datt Chambers - 1, Bhikaji Cama Place, New Delhi -110 066
    E-MAIL: complianceofficer.india@fresenius-kabi.com     WEB: www.fresenius-kabi-oncology.com
    TELEPHONE: (011) 2610 5570     FAX: (011) 2619 5965
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: MCS Limited, F-65, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi-20
    AUDITOR: G. Basu & Co.
CHM: Rakesh Bhargava COMP SEC: Nikhil Kulshreshtha YEAR OF INC: 2004 BSE CODE: 532545 FV (Rs): 1 DIV YIELD (%): -

More pharmaceuticals Company Fact Sheets:   SUVEN LIFESANOFI INDIAJ.B.CHEMICALSVENUS REMEDIESPIRAMAL ENTERPRISES


Today's Market

Global Markets Ends the Week Higher on the Back of French Election Results(RoundUp)

Financial markets received a boost earlier in the week by news that centrist Emmanuel Macron had triumphed over far-right candidate Marine Le Pen in the first round of France's presidential election.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

We Don't Want More F&O Stocks... We Need Smaller Lot Sizes(Daily Profit Hunter)

Apr 26, 2017

Are you excited to trade in the sixteen new stocks to be introduced in the F&O segment this Friday?

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

In an Ocean of Corporate Defaulters, Vijay Mallya is a Small Fish(Vivek Kaul's Diary)

Apr 20, 2017

While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.

4 Ways GST Will Impact The Mutual Fund Industry(Outside View)

Apr 19, 2017

PersonalFN explains how GST would impact India's mutual fund industry and investors

More

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS